Jilin Changlong Bio-pharmacy interim profit rises on lower costs

Jilin Province Huinan Changlong Bio-pharmacy

14/08/2026 15:37

Overview
China biochemical medicines maker's interim revenue fell 0.1% yr/yr
Net income attributable to shareholders rose for the six months ended 30 June 2026
Gross margin improved due to lower production and material costs

Outlook
Company did not provide specific financial outlook

Result Drivers
COST REDUCTIONS - Co said gross margin improved due to lower production and material costs
PRODUCTION UPGRADES - Co cited automation and equipment upgrades as improving efficiency and reducing costs
PRODUCT PORTFOLIO EXPANSION - Launch of oral solution products added to product mix

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
RMB 435 mln
 
H1 Net Income Attributable
 
RMB 122.80 mln
 

Reuters Recommended Reads
Aug 12 - China's Kangda International interim profit jumps on cost savings
Aug 13 - China's JD Health interim revenue rises on user growth, product expansion
Aug 13 - Switzerland's PolyPeptide H1 revenue rises on stronger metabolic therapeutics demand

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Press Release s3://eap-prd-eu-west-1-source-content/eap_feed_proxy/fingerpost/HKSW/2026-08-14/21a35a2f-d9c9-41af-a212-093165fcdfb5.file
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)